Get the Stockscreener App
2.45
1.24%
0.03
Pre-market:
2.45
Abcellera Biologics Inc stock is traded at $2.45, with a volume of 4.39M.
It is up +1.24% in the last 24 hours and up +0.41% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$2.42
Open:
$2.31
24h Volume:
4.39M
Relative Volume:
1.06
Market Cap:
$727.09M
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-4.7115
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
+0.41%
1M Performance:
+0.41%
6M Performance:
-11.55%
1Y Performance:
-36.69%
1-Day Range:
$2.31
$2.49
1-Week Range:
$2.31
$2.53
52-Week Range:
$1.8906
$4.3398
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
2215 YUKON STREET, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.45 | 727.09M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera Stock: Attractively Priced, But A Catalyst Is Needed (NASDAQ:ABCL) - Seeking Alpha
AbCellera (ABCL) to Engage in Upcoming Investor Conferences - GuruFocus
AbCellera (ABCL) to Release Q1 2025 Financial Results on May 8 - GuruFocus
Top Insider Buys Highlight for the Week of Dec. 18 - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June | ABCL Stock News - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India
Abcellera stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK
AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com
Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa
Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India
Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com Australia
AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa
AbCellera biologics director John Montalbano acquires $57,499 in shares - Investing.com India
Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock - Simply Wall St
Ambarella, Builders Firstsource, Sherwin-Williams, AutoZone, AbCellera: Stock Moves That Shocked the Market - TipRanks
Director Makes Bold Move with Major Stock Purchase in AbCellera Biologics - TipRanks
Abcellera Biologics director Montalbano buys $140,568 in shares By Investing.com - Investing.com South Africa
Abcellera Biologics director Montalbano buys $140,568 in shares - Investing.com
Q1 Earnings Estimate for ABCL Issued By Bloom Burton - Defense World
Sanctuary Advisors LLC Decreases Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics’ (ABCL) Hold Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Hold on AbCellera stock, no price target change - Investing.com
Benchmark maintains Hold on AbCellera stock, no price target change By Investing.com - Investing.com UK
Stifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
AbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst Downgrade - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Thursday - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
AbCellera Biologics’ Earnings Call: Transition Amid Challenges - TipRanks
Abcellera stock hits 52-week low at $2.33 amid market challenges - Investing.com India
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ... - Yahoo Finance
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):